公开(公告)号：EP4399220A1

公开(公告)日：2024-07-17

申请号：EP22785887.5

申请日：2022-09-08

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  BIRD, Gregory H.

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K47/10 ,  A61K47/28 ,  A61P31/14 ,  A61K47/60

CPC分类号： C07K14/005 ,  C12N2770/2002220130101 ,  C12N2770/2003420130101 ,  A61K39/12 ,  A61P31/14 ,  A61K47/554 ,  A61K2039/601820130101 ,  A61K2039/609320130101 ,  A61K9/0073 ,  A61K9/0043 ,  A61K9/006

公开(公告)号：EP3724216A1

公开(公告)日：2020-10-21

申请号：EP18839646.9

申请日：2018-12-14

申请人： Dana Farber Cancer Institute, Inc.

发明人： MOURTADA, Rida ,  HERCE, Henry D. ,  WALENSKY, Loren D. ,  BIRD, Gregory H. ,  MORGAN, Ann Maurine ,  BRADNER, James E.

IPC分类号： C07K14/435

公开(公告)号：EP3737404A1

公开(公告)日：2020-11-18

申请号：EP18842760.3

申请日：2018-12-13

申请人： Dana Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  BIRD, Gregory H. ,  GUERRA, Rachel ,  HARVEY, Edward

IPC分类号： A61K38/17 ,  A61M37/00 ,  C07K14/47

公开(公告)号：EP2858661B1

公开(公告)日：2020-04-22

申请号：EP12861273.6

申请日：2012-12-31

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  BIRD, Gregory H.

IPC分类号： A61K47/60 ,  A61K39/12 ,  A61K38/00 ,  C07K14/005 ,  C12N7/00

公开(公告)号：EP3270945A2

公开(公告)日：2018-01-24

申请号：EP16765822.8

申请日：2016-03-18

申请人： Massachusetts Institute of Technology ,  Dana-Farber Cancer Institute, Inc.

发明人： REZAEI-ARAGHI, Raheleh ,  KEATING, Amy ,  BIRD, Gregory H. ,  WALENSKY, Loren

IPC分类号： A61K38/16 ,  C07K7/64

CPC分类号： C07K14/4702 ,  A61K38/00 ,  A61K38/16

摘要： Provided herein are stabilized peptides that bind Mcl-1. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.

公开(公告)号：EP3962933A1

公开(公告)日：2022-03-09

申请号：EP20725283.4

申请日：2020-04-17

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  CATHCART, Ann Morgan ,  BIRD, Gregory H.

IPC分类号： C07K14/47

公开(公告)号：EP3715366A1

公开(公告)日：2020-09-30

申请号：EP20172306.1

申请日：2012-04-16

申请人： Dana Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  CARRASCO, Ruben ,  BIRD, Gregory H.

IPC分类号： C07K14/47 ,  A61K38/17 ,  A61P35/00

摘要： The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to ß-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/ß-catenin interaction, and thereby interfering with deregulated Wnt/ß-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.

公开(公告)号：EP3503924A2

公开(公告)日：2019-07-03

申请号：EP17771914.3

申请日：2017-08-25

申请人： Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： SEGAL, Rosalind ,  WALENSKY, Loren D. ,  GOODRICH, Lisa Vaughn ,  RAISSI, Sarah Elizabeth ,  MURPHY, Maria F. ,  BIRD, Gregory H.

IPC分类号： A61K45/06 ,  A61K31/337 ,  C07K14/47 ,  A61P25/02 ,  A61P25/00 ,  A61P27/16

公开(公告)号：EP4114431A2

公开(公告)日：2023-01-11

申请号：EP21714561.4

申请日：2021-03-04

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  BIRD, Gregory H.

IPC分类号： A61K38/10

公开(公告)号：EP3360892A1

公开(公告)日：2018-08-15

申请号：EP18164082.2

申请日：2012-04-16

申请人： Dana-Farber Cancer Institute, Inc.

发明人： WALENSKY, Loren D. ,  CARRASCO, Ruben ,  BIRD, Gregory H.

IPC分类号： C07K14/47 ,  A61K38/17 ,  A61P35/00

CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K38/1709 ,  A61K45/06 ,  C07K14/82 ,  G01N33/53

摘要： The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to β-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/β-catenin interaction, and thereby interfering with deregulated Wnt/β-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.